Fortress Biotech, Inc. (FBIO): Operating Cash Flow
-$65.78M
Year ended 2025-12-31
$125.92M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$65.78M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$80.19M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$128.22M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$179.40M | n/m | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | -$116.54M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$83.68M | n/m | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | -$94.96M | n/m | 2021-04-09, From 2019-01-01 |
| 2018-12-31 | -$98.85M | n/m | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | -$81.31M | n/c | 2019-03-18, From 2017-01-01 |
| 2016-12-31 | -$45.81M | n/m | 2018-03-16, From 2016-01-01 |
| 2015-12-31 | -$20.38M | n/a | 2018-03-16, From 2015-01-01 |
| No annual figure between 2013-12-31 and 2015-12-31. | |||
| 2013-12-31 | -$29.65M | n/m | 2014-03-14, From 2013-01-01 |
| 2012-12-31 | -$23.19M | n/m | 2014-03-14, From 2012-01-01 |
| 2011-12-31 | -$10.95M | n/m | 2014-03-14, From 2011-01-01 |
| 2010-12-31 | -$5.68M | n/m | 2013-03-18, From 2010-01-01 |
| 2009-12-31 | -$2.35M | n/a | 2012-03-29, From 2009-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | -$65.78M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | -$173.43M | n/m |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | -$138.89M | n/m |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | -$19.27M | n/m |
| Journey Medical Corp (DERM) | 2025-12-31 | -$12.44M | n/m |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | -$12.62M | n/m |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | -$64.06M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | -$659.0K | n/m |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $3.28M | n/m |
Compare FBIO, NUVB, TNGX, ENTA side by side · Screen every company in Pharmaceutical Preparations ↗